The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | VITAL results for birtamimab in AL amyloidosis
Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses the results of the phase III VITAL study of birtamimab (NEOD001), a monoclonal IgG1 antibody, plus standard of care in patients with light chain (AL) amyloidosis. Post hoc analyses suggest a potential survival benefit with NEOD001 for AL amyloidosis patients with the highest risk of early mortality (Mayo stage IV). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
